Last reviewed · How we verify
MR-Vac
MR-Vac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
MR-Vac is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Ovarian cancer (in development), Other solid tumors (investigational).
At a glance
| Generic name | MR-Vac |
|---|---|
| Also known as | Live attenuated measles virus and rubella virus vaccine (MR-Vac), Serum Institute of India's Measles and rubella vaccine (live) |
| Sponsor | GlaxoSmithKline |
| Drug class | Therapeutic cancer vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MR-Vac combines recombinant measles virus technology with tumor-associated antigen expression to trigger both CD8+ and CD4+ T-cell responses against cancer. The vaccine platform leverages the immunogenicity of measles virus as a carrier to enhance presentation of tumor antigens and promote durable anti-tumor immunity. This approach aims to convert immunologically cold tumors into hot tumors capable of being recognized by the patient's own immune system.
Approved indications
- Ovarian cancer (in development)
- Other solid tumors (investigational)
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
Key clinical trials
- A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) (PHASE3)
- A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants (PHASE2)
- Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |